Market closed
Unicycive Therapeutics/$UNCY
Unicycive Therapeutics shares are trading higher after the company reported Q1 results and provided a business update.
11 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Unicycive Therapeutics
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Ticker
$UNCY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
23
ISIN
US90466Y1038
Website
UNCY Metrics
BasicAdvanced
$71M
-
-$0.26
-
-
Price and volume
Market cap
$71M
52-week high
$0.69
52-week low
$0.45
Average daily volume
778K
Financial strength
Current ratio
1.64
Quick ratio
1.185
Total debt to equity
4.862
Interest coverage (TTM)
-468.21%
Management effectiveness
Return on assets (TTM)
-48.08%
Return on equity (TTM)
-92.09%
Valuation
Price to book
6.33
Price to tangible book (TTM)
6.33
Price to free cash flow (TTM)
-1.676
Growth
Earnings per share change (TTM)
-79.83%
3-year earnings per share growth (CAGR)
-35.05%
UNCY News
AllArticlesVideos
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·3 days ago
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·2 months ago
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Unicycive Therapeutics stock?
Unicycive Therapeutics (UNCY) has a market cap of $71M as of May 17, 2025.
What is the P/E ratio for Unicycive Therapeutics stock?
The price to earnings (P/E) ratio for Unicycive Therapeutics (UNCY) stock is 0 as of May 17, 2025.
Does Unicycive Therapeutics stock pay dividends?
No, Unicycive Therapeutics (UNCY) stock does not pay dividends to its shareholders as of May 17, 2025.
When is the next Unicycive Therapeutics dividend payment date?
Unicycive Therapeutics (UNCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) does not currently have a Beta indicator.